Page 6 - Opgn News Today

OpGen (NASDAQ:OPGN – Get Rating) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Friday, Zacks.com reports. According to Zacks, “OpGen, Inc. is a microbial genetics analysis company. The Company offers optical mapping services for analysis of microbial, yeast and fungal genomic […]

OpGen (NASDAQ:OPGN – Get Rating) had its target price decreased by Alliance Global Partners to $1.25 in a report released on Tuesday, The Fly reports. The firm currently has a “buy” rating on the medical research company’s stock. Alliance Global Partners’ price objective would indicate a potential upside of 78.57% from the company’s previous close. […]

OpGen (NASDAQ: OPGN) recently received a number of ratings updates from brokerages and research firms: 3/30/2022 – OpGen is now covered by analysts at StockNews.com. They set a “sell” rating on the stock. 3/22/2022 – OpGen is now covered by analysts at StockNews.com. They set a “sell” rating on the stock. 3/16/2022 – OpGen was […]

OpGen (NASDAQ:OPGN – Get Rating) released its quarterly earnings results on Tuesday. The medical research company reported ($0.35) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.16) by ($0.19), MarketWatch Earnings reports. OpGen had a negative net margin of 829.32% and a negative return on equity of 82.94%. During the same […]